1 / 15

p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study

p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study. Gastrointestinal (Non colorectal) cancer Poster discussion session Sat, June 2, 2007. The two largest trials produced conflicting results. Therapy. #. median survival. OVS 2y. p. CIS/5FU +SURGERY. 233. 15. 35%.

bliss
Télécharger la présentation

p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study Gastrointestinal (Non colorectal) cancer Poster discussion session Sat, June 2, 2007

  2. The two largest trials produced conflicting results Therapy # median survival OVS 2y p CIS/5FU +SURGERY 233 15 35% ns SURGERY vs 234 16 37% CIS/5FU +SURGERY 400 17 43% 0.004 SURGERY vs 402 13 34% …indicating moderate efficiency of standard neoadjuvant therapy INT NEJ 1988 MRC Lancet 2002

  3. Pathologic response to neoadjuvant therapy improves overall survival significanty

  4. 40% 60% Esophageal Cancer - Neoadjuvant Therapy: …Overall failure rate = p53 mutation rate (60%)…

  5. PILOT STUDY:Prospective evaluation of hypothesis 38 operable esophageal cancer patients, prospectively recruited between 2004-2006 Neoadjuvant therapy: 30 patients CIS/5FU Cisplatin 80mg/m2 d1, 5FU 1000mg/m2 d1-5 2 cycles q21d 8 patients Docetaxel off label Docetaxel 75mg/m2 2 cycles q21d

  6. The presence of p53 mutations must not be assessed by immunohistochemistry sequence analysis immunohistochemistry …sequence analysis is the golden standard

  7. Neoadjuvant treatment 1: CIS/5FU 30 patients p=0,0001

  8. Neoadjuvant treatment 2 : Docetaxel 8 patients off label *including 4 CR

  9. p53 mutation by histology p53 mutation frequency

  10. Correct response prediction in 36/38 patients (95%).

  11. p53 adjusted versus non adjusted therapy median follow up: 15,4 months p=0,042 p=0,027 Overall survival p53 adjusted p53 not adjusted months

  12. side effects costs Benefit Failure …Selection of the appropriate therapy based on the p53 genotype … could significantly improve likelihood of response

  13. PANCHO:P53 Adapted Neoadjuvant Chemotherapy for Oesophageal cancer Prospective, randomized controlled, PREDICTIVE MARKER TRIAL …designed to test the p53 predictive factor question

  14. S U R G E R Y p53 normal Patients with resectable esophageal cancer p53 gene analysis Cisplatin 80 mg/m², day 1, 3 cycles 5-FU 1000 mg/m² days 1-5; q 21,3 cycles Pancho : trial design Cisplatin 80 mg/m², day 1, 3 cycles 5-FU 1000 mg/m² days 1-5; q 21,3 cycles randomize stratify * Docetaxel 75 mg/m², day 1, q 21, 3 cycles p53 mutant stratify * randomize Docetaxel 75 mg/m², day 1, q 21, 3 cycles * Stratification for adeno- and squamous cell cancer Primary endpoint: RESPONSE to neaoadjuvant therapy

  15. PANCHO • Start: Mai 2007 • 84 patients to be randomized within 18 months • Intended bywww.p53.at • Sponsored by the ASSO (Austrian Society for Surgical Oncology)

More Related